Dysregulation of the pancreatic endoplasmic reticulum kinase branch of the UPR and its downstream target, eukaryotic initiation factor 2 (eIF2α), have been identified as potential targets in the treatment of AD [6], but no safe and effective drugs acting on this pathway exist. The gene discussed is EIF2A; the disease is Alzheimer disease.